Related Experiment Video
Updated: Jun 17, 2026
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Immunogenicity of Haemophilus influenzae type b conjugate vaccines in Korean infants: a meta-analysis
Hyunju Lee1, Seokyung Hahn, Hoan Jong Lee
1Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea.
Insights
A meta-analysis found Haemophilus influenzae type b (Hib) tetanus toxoid conjugate vaccine (PRP-T) immunogenicity in Korean infants. Two doses achieved 80.6% protective antibody levels, while three doses reached 95.7%.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Public Health
Background:
- Haemophilus influenzae type b (Hib) conjugate vaccines are crucial for infant immunization.
- Assessing vaccine immunogenicity ensures effective protection against Hib disease.
- Korean infant vaccination schedules require evaluation for optimal Hib conjugate vaccine efficacy.
Purpose of the Study:
- To evaluate the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines in Korean infants.
- To compare the immune response after 2-dose versus 3-dose primary vaccination series.
- To determine the proportion of infants achieving protective anti-polyribosylribitol phosphate (PRP) antibody concentrations.
Main Methods:
- Meta-analysis of published studies on Hib conjugate vaccine immunogenicity in Korean infants.
- Database searches of MEDLINE, KoreaMed, and Korean Medical Database.
- Primary outcome: proportion of infants with anti-PRP antibody concentrations ≥1.0 µg/mL.
Main Results:
- Meta-analysis focused on the tetanus toxoid conjugate vaccine (PRP-T) due to heterogeneity in other vaccine types.
- After a 2-dose primary series (2 and 4 months), 80.6% of infants achieved protective PRP antibody levels.
- Following a 3-dose primary series (2, 4, and 6 months), 95.7% of infants reached protective PRP antibody levels.
Conclusions:
- The PRP-T vaccine demonstrates acceptable immunogenicity in Korean infants after both 2-dose and 3-dose primary series.
- A 2-dose primary vaccination schedule for Hib conjugate vaccines may be considered for Korean infants.
- Further consideration of reduced dosing schedules could optimize infant immunization strategies.
Abstract:
A meta-analysis was performed on the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines after 2 (2 and 4 months) and 3 doses (2, 4, and 6 months) in Korean infants. A database search of MEDLINE, KoreaMed, and Korean Medical Database was done. The primary outcome measure was the proportion of infants with anti-polyribosylribitol phosphate (PRP) concentrations > or =1.0 microg/mL. Eight studies including eleven trials were retrieved. One trial reported on the diphtheria toxoid conjugate vaccine (PRP-D) and 2 trials each on the mutant diphtheria toxin (PRP-CRM) and Neisseria meningitidis outer-membrane protein (PRP-OMP) conjugate vaccine. Heterogeneity in study designs between trials on PRP-CRM was noted and one trial reported on a monovalent and another on a combination PRP-OMP vaccine. Thus, a meta-analysis was conducted only on the tetanus toxoid conjugate vaccine (PRP-T). After a primary series of 2 doses and 3 doses, 80.6% (95% confidence interval [CI]; 76.0-85.1%) and 95.7% (95% CI; 94.0-98.0%) of infants achieved an antibody level > or =1.0 microg/mL, respectively. The immunogenic response to the PRP-T vaccine was acceptable after a primary series of 3 doses and also 2 doses. A reduced number of doses as a primary series could be carefully considered in Korean infants.
